[Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
Jarlier
V
V
Groupe hospitalier Pitié-Salpêtrière, Paris.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology*; D001441:Bacteroides fragilis / Q000187:drug effects; D019818:Clavulanic Acid / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D007711:Klebsiella pneumoniae / Q000187:drug effects; D001936:Moraxella catarrhalis / Q000187:drug effects; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011514:Proteus vulgaris / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam